Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digoxin for Congenital Erythrocytosis
NCT03433833Phase 1Withdrawn
- Sponsor
- University of Illinois Chicago
- Start
- Nov 2019
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of digoxin in congenital erythrocytosis (CE), sponsored by University of Illinois Chicago. Primary endpoint: Hemoglobin concentration at 24 weeks. Planned start Nov 2019; status: withdrawn.
02
Drugs
digoxin
03
Conditions
congenital erythrocytosis (CE)
Beyond the preview
Go deeper on NCT03433833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03433833.